Buy Takhzyro (lanadelumab)

What is Takhzyro (lanadelumab)?

Takhzyro (lanadelumab) is a medicine for the prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. It is available as solution for injection in single-dose, ready-to-use vials^[1,2].

How does Takhzyro (lanadelumab) work?

Hereditary angioedema (HAE) is a disease characterised by recurrent attacks of severe swelling of the skin and mucous membranes on areas like the face, throat, arms and legs^[2,3].

Patients with hereditary angioedema have high levels of an inflammatory agent called bradykinin, an active peptide that causes blood vessels to enlarge and release fluid into other tissues resulting in swelling^[4]. Kinin-kallikrein system is a hormonal system that produces the bioactive agent, bradykinin. The active ingredient in Takhzyro, lanadelumab, is a plasma kallikrein inhibitor (monoclonal antibody) which blocks the action of kallikrein in the blood and decreases the symptoms of the disease^[4].

Where has Takhzyro (lanadelumab) been approved?

Takhzyro (lanadelumab) was approved for the prevention of recurrent attacks of hereditary angioedema (HAE) by:

• Food and Drug Administration (FDA), USA, August 23, 2018^[1]
• European Medical Agency (EMA), European Union, November 22, 2018^[2].

Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.

How is Takhzyro (lanadelumab) taken?

The standard dosage is^[1,2]:

• 300 mg taken as a subcutaneous (under-the-skin) injection that you give yourself once every 2 weeks.

Reduction in dose may be required based on symptoms and experienced side effects.

Complete information about Takhzyro (lanadelumab) dosage and administration can be found in the official prescribing information listed in our resources section.

Note: Please consult with your treating doctor for personalised dosing and potential drug interactions.

Are there any known side effects or adverse reactions of Takhzyro (lanadelumab)?

The most common adverse reactions listed in the prescribing information include:

• injection site reactions, such as:
  • pain
  • skin redness
  • bruising
  • discomfort
  • swelling.

Takhzyro (lanadelumab) can be fatal for a foetus, it is advised to avoid pregnancies and breastfeeding while taking this medicine.

For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information^[1,2].

References

1. Summary of Product Characteristics [FDA]: Takhzyro (lanadelumab)[PDF]

Dyax Corp., August 2018.

2. Summary of Product Characteristics [EMA]: Takhzyro (lanadelumab)[PDF]

Shire Pharmaceuticals Ireland Ltd, November 2018.

3. US National Institute of Health,Hereditary angioedema, cited on 22/02/2019.
4. EMA Human Medicines: Takhzyro (lanadelumab)

17/12/2018, cited on: 22/02/2019.